Clinical Trials
9 trialsNCT04433156 2026-04-09
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
Henan Cancer Hospital
Phase 2 Completed
NCT04214626 2025-11-19
R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
Phase 2 Completed
NCT07233720 2025-11-18
Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma
Henan Cancer Hospital
Recruiting
NCT04668365 2025-04-25
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
Phase 2 Suspended
NCT03245021 2024-07-30
1stFLOR
Austin Health
Phase 1 Active not recruiting
NCT02747732 2019-04-23
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
Sheba Medical Center
Phase 2 Unknown
NCT00280878 2016-01-15
Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma
Bayside Health
Phase 2 Completed
NCT00127569 2007-01-12
Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy
French National Agency for Research on AIDS and Viral Hepatitis
Phase 2 Terminated
NCT00126243 2005-08-17
Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma
French National Agency for Research on AIDS and Viral Hepatitis
Phase 2 Terminated